-
Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar
Thursday, October 3, 2019 - 3:49pm | 1635Pfenex Inc (NYSE: PFNX) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. Through its production platform Pfenex Expression Technology, the biotech Pfenex engages in the development of high-value...
-
Second Time's The Charm For Amgen As FDA OKs Bone-Building Osteoporosis Drug
Wednesday, April 10, 2019 - 9:44am | 462Amgen, Inc. (NASDAQ: AMGN) — which was in the news late last week over a legal battle with Novartis AG (NYSE: NVS) over their migraine drug collaboration — now has a positive FDA decision to celebrate. Unique Drug Cleared Amgen announced late Tuesday the FDA approved...